MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
|Articles|July 11, 2012
Drug Cost Control in Oncology
Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.
Advertisement
Advertisement
Related to this article
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5